In addition, preliminary analysis of blinded data from nearly 4,000 patients participating in a series of four ongoing Phase III trials supports that the naltrexone sustained release (SR)
Joseph Papa, chairman and CEO of Perrigo, said: “The acquisition of Laboratorios Diba will enable us to market an additional 150 formulas and 50 trademarks into the rapidly
Under the terms of the asset acquisition agreement, the company will pay an aggregate cash consideration of $345 million in installments with the final payment to be made
The results from the Phase II prospective randomized placebo-controlled study of 125 patients with advanced prostate cancer after four years of follow-up show that patients receiving Prostvac had
This study demonstrates that the protocol-specified, intent-to-treat, primary endpoint comparison of a six-month course of rifaximin at 550mg dosed twice-a-day provides a highly statistically significant result in preventing
The data showed that Cimzia (certolizumab pegol) – the only PEGylated anti-TNF alpha (tumor necrosis factor alpha) – significantly improved endoscopic lesions and induced endoscopic response (as assessed
Mr Slattery is currently on the boards of Micromet, a biopharmaceutical company, and TranS1, a medical device company. Mr Slattery also served as senior vice president and CFO
According to the company, Rapid 5 Access brings many advantages to the capsule endoscopy program: it utilizes existing computers and network system to create, manage and store PillCam
Mr Cooper, who was serving as interim chairman, will be stepping down from the board to focus on his activities as a director at Grant Samuel. Mr Drona
In its summary judgment ruling, the court found that the administration of Enbrel falls outside the scope of the asserted claims based on the court’s interpretation of these
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.